hrp0089p1-p064 | Diabetes & Insulin P1 | ESPE2018

Efficacy of Mecasermin Treatment and Long-Term Survival in a Child with Leprechaunism

Maggio Maria Cristina , Barbetti Fabrizio , Vitaliti Marcello , Ragusa Saveria Sabrina , Vitaliti Giuliana , Corsello Giovanni

Homozygous mutation of Insulin receptor (INS-R) gene cause an extremely rare disease called Leprechaunism, and induce intrauterine growth restriction with poor postnatal growth, hyperinsulinemia, postprandial hyperglycaemia, pre-prandial hypoglycaemia, typical facies, lack of subcutaneous fat, thick skin, hypertrichosis, macrogenitosomia in males. The survival is severely compromised in these patients. Treatment with diazoxide could ameliorate glycaemic control, however these ...

hrp0082p3-d1-706 | Diabetes | ESPE2014

Congenital Hyperinsulinism Linked to INS-R Mutation: Case Report

Vitaliti Marcello , Maggio Maria Cristina , Vitaliti Giuliana , Grasso Valeria , Ciofalo Amalia , Rinaudo Grazia , Tranchina Elisa , Costantino Giuseppina , Corsello Giovanni , Barbetti Fabrizio

Background: Leprechaunism, also known as Donohue syndrome, is due to a severe congenital insulin-resistance, with prenatal and neonatal growth retardation, typical dysmorphic features, glycaemic dysregulation with hyperinsulinism and hyperandrogenism.Objective and hypotheses: These patients have a poor prognosis with death in the first year of life.Method: We report the case of a newborn (35.4 weeks) with severe fetal growth restri...

hrp0095p1-247 | Diabetes and Insulin | ESPE2022

Monogenic diabetes clinic: 3-year experience

Rapini Novella , Ippolita Patera Patrizia , Schiaffini Riccardo , Ciampalini Paolo , Pampanini Valentina , Cristina Matteoli Maria , Deodati Annalisa , Bracaglia Giorgia , Porzio Ottavia , Novelli Antonio , Mucciolo Mafalda , Cianfarani Stefano , Barbetti Fabrizio

Background: In Italy monogenic forms of hyperglycemia account for more than 6% of cases referred to pediatric diabetes clinics. In January 2019 we started a Monogenic Diabetes Clinic (MDC) with the three main aims: a) implementing a standardized pathway towards genetic testing, 2) ease the revision of complex cases, 3) implement standardized therapies for monogenic diabetes mellitus (MDM) subtypes.Methods: Type 1 diabete...